Cross-talk among oncogenic signaling and metabolic pathways may create opportunities for new therapeutic strategies in cancer. Here we show that although acute inhibition of EGFR-driven glucose metabolism induces only minimal cell death, it lowers the apoptotic threshold in a subset of patient-derived glioblastoma (GBM) cells. Mechanistic studies revealed that after attenuated glucose consumption, Bcl-xL blocks cytoplasmic p53 from triggering intrinsic apoptosis. Consequently, targeting of EGFR-driven glucose metabolism in combination with pharmacological stabilization of p53 with the brain-penetrant small molecule idasanutlin resulted in synthetic lethality in orthotopic glioblastoma xenograft models. Notably, neither the degree of EGFR-signaling inhibition nor genetic analysis of EGFR was sufficient to predict sensitivity to this therapeutic combination. However, detection of rapid inhibitory effects on [ 18 F]fluorodeoxyglucose uptake, assessed through noninvasive positron emission tomography, was an effective predictive biomarker of response in vivo. Together, these studies identify a crucial link among oncogene signaling, glucose metabolism, and cytoplasmic p53, which may potentially be exploited for combination therapy in GBM and possibly other malignancies.
Molecularly targeted therapies have revolutionized cancer treatment and paved a path for modern precision medicine. However, despite well-defined actionable genetic alterations 1 , targeted drugs have failed in patients with GBM, largely because of insufficient brain penetration of most targeted agents to levels necessary for tumor killing 2 . This insufficient abundance in the target tissue may induce the development of adaptive mechanisms that drive drug resistance 3 . Whereas therapeutic combinations that target both the primary genetic lesion and the compensatory signaling pathways that promote resistance are appealing, these combination-therapy strategies have been hampered by toxicity, thereby requiring subthreshold dosing of each drug 4, 5 . Owing to the dismal prognosis for patients with GBM and the poor efficacy of conventional approaches, new therapeutic strategies are critically needed.
An alternative therapeutic approach-synthetic lethality-targets an oncogenic driver and consequently modifies an important functional property for tumorigenesis, thus rendering cells vulnerable to an orthogonal 'second hit' 6 . This strategy may be particularly attractive when oncogene-regulated functional networks modulate pathways of tumor cell death. In a notable example, oncogenic signaling drives glucose metabolism, thereby suppressing the intrinsic (or mitochondria-dependent) apoptotic pathway and preventing cell death 7, 8 . Consequently, inhibition of oncogenic drivers with targeted therapies may trigger the intrinsic apoptotic machinery as a direct consequence of attenuated glucose consumption. The intertwined nature of these tumorigenic pathways could present therapeutic opportunities for rationally designed combination treatments, but this possibility has yet to be investigated.
Previous work has demonstrated that the epidermal growth factor receptor (EGFR) is mutated and/or amplified in ~60% of patients with GBM 9 and regulates glucose metabolism 10 . Whether targeting EGFR-driven glucose utilization alters the dynamics of the intrinsic apoptotic machinery in cancer is unknown. Here we hypothesized that a deeper understanding of this relationship might reveal a pharmacological vulnerability allowing for enhanced tumor killing in GBM.
RESULTS

EGFR-inhibitor metabolic responders and nonresponders
We first characterized the changes in glucose uptake induced by acute EGFR inhibition across 19 patient-derived GBM cell lines. The cells were cultured as gliomaspheres in supplemented serumfree medium, conditions that, in contrast to serum-based culture conditions, preserve many of the molecular features of patient tumors 11, 12 . Treatment with the EGFR tyrosine kinase inhibitor erlotinib revealed a subset of GBMs, hereafter termed 'metabolic responders' , in which uptake of radiolabeled glucose ([ 18 F]fluorodeo xyglucose, denoted [ 18 F]FDG) was significantly attenuated (Fig. 1a and Supplementary Fig. 1a) . Silencing of EGFR with siRNA confirmed that the decrease in glucose uptake was not due to off-target effects of erlotinib ( Supplementary Fig. 1b,c) . As determined in a randomly selected cohort of metabolic responders, lower [ 18 F]FDG uptake was associated with lower lactate secretion, glucose consumption, and extracellular acidification rate (ECAR), yet glutamine levels remained unchanged ( Fig. 1b and Supplementary Fig. 1d-g ).
Suppressed glucose utilization also correlated with a decrease in signaling of the RAS-MAPK and PI3K-AKT-mTOR pathways, each of which regulates glucose metabolism in GBM and other cancers 10, 13, 14 ( Supplementary Fig. 2a) .
In contrast, no nonresponder GBMs ( Fig. 1a and Supplementary  Fig. 1b,c) showed decreased glucose consumption, lactate secretion, or ECAR, despite robust inhibition of EGFR activity (Fig. 1b and  Supplementary Figs. 1d-g and Supplementary Fig. 2b) . Moreover, RAS-MAPK and PI3K-AKT-mTOR signaling was unchanged in nearly all metabolic nonresponders (Supplementary Fig. 2b) . Notably, whereas all metabolic responders had alterations in EGFR (mutation and/or amplification, or polysomy), six GBM lines without metabolic responses also contained EGFR mutations and/or copynumber gains (Supplementary Fig. 3a,b) . Together, these data illustrate two key points. First, acute inhibition of EGFR rapidly attenuates glucose utilization in a subset of primary GBM cells, and second, genetic alterations in EGFR alone cannot predict which GBMs have a metabolic response to EGFR inhibition. The concentration of erlotinib was selected to achieve robust inhibition of EGFR activity across the panel of primary GBM cells (additional data in Supplementary Fig. 2 ). Metabolic responders (blue) are samples that showed a significant decrease in [ 18 F]FDG uptake relative to vehicle; nonresponders (red) showed no significant decrease (mean ± s.d.). Number of gliomasphere samples (n) = 3 for GBM39, HK248, HK301, HK385, HK423, HK206, HK217, HK250, HK254, HK350, HK393, GS017, and GS025; n = 4 for HK229; n = 5 for HK390; n = 6 gliomasphere samples for HK157, HK296, HK336, GS024).
(b) Percentage change in glucose consumption and lactate secretion after 12 h of 1 µM erlotinib treatment relative to vehicle. Measurements were made with a Nova Biomedical BioProfile Analyzer (mean ± s.d.). For glucose consumption: n = 5 for HK390, HK217, and HK393; n = 4 for GBM39, HK301, and HK254. For lactate secretion: n = 5 for HK390, GBM39, and HK301; n = 3 for HK217, HK393, and HK254. (c) Annexin V staining of metabolic responders (blue, n = 10 unique gliomaspheres) or nonresponders (red, n = 9 unique gliomaspheres) after treatment with 1 µM erlotinib for 72 h. Each point represents the mean apoptosis of two independent experiments conducted for each gliomasphere sample. (d) The percentage change, relative to vehicle control, in priming, as determined by cytochrome c release after exposure to each BH3 peptide (BIM, BID, or PUMA) in metabolic responders or nonresponders treated with 1 µM erlotinib for 24 h (mean ± s.d., n = 2). Statistical analysis was performed on the grouped metabolic responders versus nonresponders. Results are representative of two independent experiments. (e) Left, immunoblot of whole cell lysates of HK301 cells overexpressing GFP control or GLUT1 and GLUT3 (GLUT1/3). Right, changes in glucose consumption or lactate secretion of HK301-GFP or HK301-GLUT1/3 after 12 h of 1 µM erlotinib treatment. Values are relative to vehicle control (mean ± s.d.). For glucose consumption: n = 4 for HK301-GFP; n = 5 for HK301-GLUT1/3. For lactate secretion: n = 7 for HK301-GFP; n = 5 for HK301-GLUT1/3. β-actin, loading control. Uncropped images of gels are shown in Supplementary Figure 12. (f) As in d, using HK301-GFP or HK301-GLUT1/3 cells (left) or GBM39-GFP or GBM39-GLUT1/3 cells (right). In the box plots, the central rectangle spans the first quartile to the third quartile (i.e., the interquartile range (IQR)), the central line inside the rectangle shows the mean, and whiskers above and below the box show the locations of the minimum and maximum within 1.5× the IQR, respectively. Comparisons were made with two-tailed unpaired Student's t tests. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Metabolic responders are primed for apoptosis Perturbations in glucose metabolism can induce the expression of proapoptotic factors and promote intrinsic apoptosis 15 , leading us to posit that decreased glucose uptake in response to EGFR inhibition would stimulate the intrinsic apoptotic pathway. Indeed, acute erlotinib treatment enhanced the expression of the proapoptotic BH3-only proteins BIM and PUMA, only in the metabolic-responder cultures (Supplementary Fig. 4a ). However, annexin V staining revealed that metabolic responders had only modest (~17% of cells annexin V positive), albeit significantly higher, apoptosis than did nonresponders (~3% of cells annexin V positive) after 72 h of erlotinib exposure (Fig. 1c) .
The relatively low level of apoptosis in metabolic-responder GBMs, despite pronounced induction of proapoptotic factors, led us to ask whether perturbing glucose uptake with erlotinib simply 'primes' GBM cells for apoptosis, thus increasing the propensity for apoptosis without inducing considerable cell death 16 . The induction of a primed apoptotic state, or a shift in the threshold for cell death, can be measured by BH3 profiling 17 . This profiling determines the proximity of cells to intrinsic apoptosis after exposure of the mitochondria of drug-treated cells to synthetic proapoptotic BH3 peptides (for example, BIM, BID, and/or PUMA) and then quantifying the changes in mitochondria potential, as assessed on the basis of cytochrome c release. Accordingly, we treated both metabolic responders and nonresponders for 24 h and performed BH3 profiling by using multiple BH3 peptides across various concentrations ( Supplementary  Fig. 4b ). We observed heightened apoptotic priming-as determined by the change in cytochrome c release relative to vehicle-in the metabolic responders with erlotinib treatment (Fig. 1d) . Notably, priming in metabolic responders was significantly higher than priming in nonresponders (Fig. 1d) , supporting the premise that attenuated glucose uptake with EGFR inhibition triggers apoptotic priming in GBM.
We reasoned that if decreased glucose uptake is required for apoptotic priming after EGFR targeting, rescuing glucose consumption should mitigate these effects. Given that EGFR inhibition can abrogate the expression and localization of glucose transporters 1 and 3 (GLUT1 and GLUT3, respectively) 10 (Supplementary Fig. 5a ), we ectopically expressed both GLUT1 and GLUT3 in two metabolicresponder GBMs (HK301 and GBM39) to sustain glucose flux under erlotinib treatment. Enforced expression of GLUT1 and GLUT3 (denoted GLUT1/3) rescued erlotinib-mediated attenuation of glucose consumption and lactate secretion in both cell lines ( Fig. 1e and Supplementary Fig. 5b-d ) and markedly suppressed apoptotic priming in response to EGFR inhibition (Fig. 1f) . Collectively, these data demonstrate that erlotinib-mediated inhibition of glucose metabolism, although insufficient to induce meaningful cell death, lowers the apoptotic threshold and potentially renders GBM cells vulnerable to agents that exploit this primed state.
Cytoplasmic p53 is required for apoptotic priming Next, we investigated the mechanism by which GBMs become primed for apoptosis after treatment with erlotinib. In primed cells, the antiapoptotic Bcl-2 family proteins (for example, Bcl-2, Bcl-xL, and Mcl-1) are largely loaded with proapoptotic BH3 proteins (for example, BIM, BID, PUMA, BAD, NOXA, and HRK); consequently, cells are dependent on these interactions for survival 16 . The tumorsuppressor protein p53 increases expression of proapoptotic proteins that subsequently must be sequestered by antiapoptotic Bcl-2 proteins to prevent cell death 18 . To examine whether p53 is required for erlotinib-induced priming, we abrogated p53 expression in two metabolic responders (HK301 and HK336) using CRISPR-Cas9 targeting TP53; the resulting cells are hereafter referred to as p53KO (Fig. 2a) . Although the change in glucose uptake with erlotinib was unaffected in p53KO cells (Supplementary Fig. 6a ), BH3 profiling revealed that p53KO exhibited nearly abolished erlotinib-induced apoptotic priming (Fig. 2b) . (d) Immunofluorescence of p53 protein combined with DAPI nuclear staining to reveal protein localization in HK301 sgCtrl, p53KO + p53 cyto , and p53KO + p53 WT (scale bars, 20 µm). (e) Changes in levels of the indicated mRNAs after 100 nM doxorubicin treatment for 24 h in HK301 sgCtrl, p53KO, p53KO + p53 cyto , and p53KO + p53 WT . Levels were normalized to respective dimethyl sulfoxide (DMSO)-treated cells (mean ± s.d., n = 3). (f) As in b, but in HK301 sgCtrl, p53KO, p53KO + p53 cyto , and p53KO + p53 WT (mean ± s.d., n = 2). Results are representative of two independent experiments. (g) As in e, but in HK301 sgCtrl, p53KO, p53KO + p53 R175H , p53KO + p53 R273H , and p53KO + p53 NES (mean ± s.d., n = 3). (h) As in b and f, but in HK301 sgCtrl, p53KO, p53KO + p53 R175H , p53KO + p53 R273H , and p53KO + p53 NES (mean ± s.d., n = 2). Results are representative of two independent experiments. Comparisons were made with two-tailed unpaired Student's t tests. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; NS, not significant.
Because transcription of p53-target genes has been shown to be enhanced under glucose limitation 15, 19, 20 , we tested whether p53-mediated transcription was induced by EGFR inhibition. Erlotinib neither increased the expression of p53-regulated genes (for example, CDKN1A (also known as P21), MDM2, PIG3 (official symbol TP53I3), and TIGAR) (Supplementary Fig. 6b ) nor induced p53-luciferase reporter activity in HK301 metabolic-responder cells (Supplementary Fig. 6c ), indicating that although p53 is required for priming with EGFR inhibition, its transcriptional activity may not be necessary.
In addition to p53's well-described nuclear functions, p53 can localize in the cytoplasm, where it directly engages the intrinsic apoptotic machinery via interactions with proapoptotic and/or antiapoptotic Bcl-2 family members 21, 22 . To evaluate whether cytoplasmic p53 is important for apoptotic priming with erlotinib, we stably introduced a p53 mutant with a defective nuclear-localization signal (p53 cyto ) 23 into HK301 and HK336 p53KO gliomaspheres. As expected, p53 cyto was expressed ( Fig. 2c and Supplementary Fig. 6d ) in a manner restricted to the cytoplasm ( Fig. 2d and Supplementary Fig. 6e ) and had no transcriptional activity ( Fig. 2e and Supplementary Fig. 2f ). In contrast, reconstitution of wild-type p53 (p53 WT ) in HK301 and HK336 p53KO cells displayed a localization of p53 similar to that observed in the parental cells, and p53 WT reconstitution rescued transcription of p53-regulated genes (Fig. 2c-e and Supplementary Fig. 6d-f) . Stable introduction of p53 cyto significantly restored priming with erlotinib in both HK301 and HK336 p53KO cells to levels comparable to those of p53 WT ( Fig. 2f and Supplementary Fig. 6g ), indicating that the cytoplasmic function of p53 is required for erlotinib-mediated priming. In support of this conclusion, introduction of a transcriptionally active ( Fig. 2g ) yet nuclear-confined p53 mutant (p53 NES ) into HK301 p53KO cells did not induce erlotinib-mediated apoptotic priming (Fig. 2g,h and Supplementary Fig. 6h ). Finally, pharmacological inhibition of cytoplasmic-p53 activity with pifithrin-µ (ref. 24) markedly decreased priming with erlotinib ( Supplementary Fig. 6i ). Collectively, these results show that cytoplasmic p53 engages the intrinsic apoptotic machinery after treatment with erlotinib in GBM metabolic-responder samples.
Prior work has demonstrated that TP53 mutations detected in human tumors-specifically those in the DNA-binding domainresult in diminished cytoplasmic functions in addition to transactivation deficiencies 22, 25 . Thus, we asked whether stable expression of either of two of these 'hotspot' p53 mutants, R175H and R273H, in HK301 p53KO cells might decrease EGFR-inhibitor-mediated apoptotic priming (Supplementary Fig. 6h ). As expected, both mutants lacked transcriptional capabilities ( Fig. 2g) and, in agreement with their low cytoplasmic activity, were incapable of priming with erlotinib ( Fig. 2h) . Therefore, in line with previous findings, oncogenic mutations in the DNA-binding domain of p53 result in 'dual hits' 26 , whereby both transactivation and cytoplasmic functions are abrogated, the latter having implications for apoptotic priming with EGFR inhibition. In agreement with the notion that erlotinib-mediated apoptotic priming of metabolic responders requires a functional p53, all metabolic responders lacked mutations in p53 (Supplementary Fig. 3a) . 
Inhibition of glucose uptake creates therapeutic vulnerability
Bcl-xL can sequester cytoplasmic p53 and prevent p53-mediated apoptosis, thus creating a primed apoptotic state and a dependency on Bcl-xL for survival 27 . Indeed, BH3 profiling revealed a reliance on Bcl-xL to block apoptosis initiation in erlotinib metabolic responders ( Supplementary Fig. 7a ). Therefore, we hypothesized that attenuated glucose consumption with EGFR inhibition might result in the sequestration of cytoplasmic p53 by Bcl-xL. To investigate this possibility, we performed coimmunoprecipitation to examine the dynamics of p53-Bcl-xL interactions in response to erlotinib in both responders (n = 2) and nonresponders (n = 2). Importantly, we observed increased formation of Bcl-xL-p53 complexes with erlotinib treatment in metabolic responders ( Fig. 3a) but not in nonresponders (Fig. 3b) . This result suggests that inhibition of EGFR-dependent glucose consumption results in sequestration of p53 by Bcl-xL. In agreement with this interpretation, ectopic expression of GLUT1/3, which rescued the erlotinib-mediated decrease in glucose uptake and apoptotic priming, prevented the association of p53 with Bcl-xL in two metabolic responders (HK301 and GBM39) ( Fig. 3c and Supplementary Fig. 7b ). These findings strongly indicate that erlotinib-mediated inhibition of glucose uptake primes GBM cells for apoptosis by promoting interaction between cytoplasmic p53 and Bcl-xL. Disruption of the p53-Bcl-xL complex can 'free' cytoplasmic p53, thus allowing it to stimulate intrinsic apoptosis 27 . In light of the result that binding between Bcl-xL and p53 increases in metabolic responders in response to erlotinib, we asked whether the liberation of p53 from Bcl-xL might elicit apoptosis. To test this possibility, we treated a metabolic responder (HK301) with erlotinib and the specific Bcl-xL inhibitor WEHI-539 (ref. 28 ). The addition of WEHI-539 released p53 from Bcl-xL under erlotinib treatment (Fig. 3d) , thereby leading to synthetic lethality in three metabolic responders (HK301, GBM39, and HK336) ( Fig. 3e and Supplementary Fig. 7c) . Notably, cytoplasmic p53 was sufficient for caspase-dependent apoptosis elicited by the drug combination ( Supplementary Fig. 7c,e) . However, WEHI-539 did not enhance apoptosis in a nonresponder (HK393) treated with erlotinib, thus suggesting that attenuation of glucose uptake with EGFR inhibition, and subsequent association between p53 and Bcl-xL, is necessary to lower the apoptotic threshold and generate a dependence on Bcl-xL for survival (Fig. 3e) . In support of this possibility, enforced expression of GLUT1/3 significantly mitigated cell death with the drug-combination treatment in both HK301 and GBM39 cells ( Fig. 3f  and Supplementary Fig. 7d ). Together, these observations indicate that Bcl-xL blocks GBM cell death in response to erlotinib-mediated inhibition of glucose metabolism by sequestering cytoplasmic p53.
Combination-treatment efficacy in metabolic responders
Our mechanistic studies revealed a potential therapeutic opportunity in EGFR-driven GBMs that is dependent on functional p53. Although the p53 signaling axis is one of the three core pathways altered in GBM 1, 29 , analysis of the GBM data set from TCGA demonstrated that TP53 mutations were mutually exclusive with alterations in EGFR (Fig. 4a,b) . In contrast, in most patients with EGFR The dose titration of erlotinib and nutlin, as described in c, was conducted across ten metabolic responders and five nonresponders (all wild-type p53), and the synergy score was calculated (Online Methods) (mean ± s.d., number of gliomasphere samples (n) = 2). The dashed line indicates a synergy score of 1. Results are representative of two independent experiments. (e) Annexin V staining of HK301-GFP and HK301-GLUT1/3 after 72 h of treatment with 1 µM erlotinib, 2.5 µM nutlin, or both (mean ± s.d., n = 3). Results are representative of two independent experiments. (f) As in e, but in HK301 sgCtrl and HK301 p53KO (mean ± s.d., n = 3). Results are representative of two independent experiments. (g) HK301 was treated for 24 h with 1 µM erlotinib, 2.5 µM nutlin, or both in combination. Immunoprecipitation was performed with immunoglobulin G control antibody or anti-p53 antibody, and the immunoprecipitate was probed with the indicated antibodies. Below are respective preimmunoprecipitation lysates (input). β-actin, loading control. Comparisons were made with two-tailed unpaired Student's t tests. **P < 0.01; ***P < 0.001; ****P < 0.0001. Uncropped images of gels are shown in Supplementary Figure 12. mutations or gains, co-occurring alterations can lead to suppressed p53 activity, including amplification of MDM2 and/or deletions in p14 ARF, a negative regulator of MDM2, at the CDKN2A locus 30, 31 ( Fig. 4a,b) . Given these relationships, and the requirement of p53 for priming under erlotinib-attenuated glucose uptake, we hypothesized that stabilization of p53 via MDM2 inhibition might have similar therapeutic effects to Bcl-xL antagonism. Using nutlin, an extensively characterized inhibitor of MDM2 (ref. 32), we observed synthetic lethality in combination with erlotinib treatment in a metabolicresponder gliomasphere. More than 90% of HK301 cells underwent apoptosis after combined erlotinib and nutlin treatment (Fig. 4c) . In contrast, we observed no synergy between these drugs in a metabolic nonresponder (HK393; Fig. 4c) . We then tested this combination across our panel of primary GBM cells (all wild-type p53) and found synthetic lethality only in GBMs with a metabolic response to erlotinib, albeit to a lesser extent in HK423 and HK296 metabolic responders ( Fig. 4d and Supplementary Fig. 8a ; methodology in ref. 33 ). Silencing of EGFR in combination with nutlin also showed selective synergy for metabolic-responder cells, thus suggesting that the effects of the drug combination were not due to off-target effects of erlotinib (Supplementary Fig. 8b) . Importantly, enforced expression of GLUT1/3 in HK301 metabolic responder cells significantly decreased molecular markers of intrinsic apoptosis-including BAX oligomerization and cytochrome c release-as well as cell death after combined erlotinib and nutlin treatment ( Fig. 4e and Supplementary  Fig. 8c) , thus supporting the concept that attenuated glucose metabolism with EGFR inhibition is required for the synthetic lethality of the drug combination.
Metabolic responder Nonresponder
We next investigated the role of p53 in eliciting cell death in response to combined erlotinib and nutlin treatment. As expected, p53KO in two erlotinib metabolic responders (HK301 and HK336) abolished sensitivity to the drug combination ( Fig. 4f and Supplementary Fig. 8g) . Likewise, ectopic expression of Bcl-xL markedly suppressed cell death after combined treatment, in agreement with a critical function for Bcl-xL in antagonizing p53-mediated apoptosis ( Supplementary  Fig. 8d) . Moreover, similar to our results with Bcl-xL inhibition (for example, WEHI-539), the addition of nutlin liberated p53 from Bcl-xL under erlotinib treatment (Fig. 4g) . These data are consistent with prior observations that p53 stabilization stimulates cytoplasmic-p53-mediated apoptosis 27, 34 . In support of the suggestion that cytoplasmic-p53 activity is required for the synergy of erlotinib and nutlin in metabolic responders, blocking cytoplasmic-p53 activity with pifithrin-µ significantly mitigated apoptosis elicited by combination treatment (Supplementary Fig. 8e) , whereas HK301 cells containing the nuclear-confined p53 mutant p53 NES did not show enhanced cell death when treated with the drug combination ( Supplementary  Fig. 8f) . Finally, cells expressing the cancer-hotspot p53 mutants R175H and R273H, which have both transactivation and cytoplasmic deficiencies, were completely insensitive to the erlotinib and nutlin combination (Supplementary Fig. 8f ).
Whereas cytoplasmic p53 was absolutely required to promote cell death with combined erlotinib and nutlin treatment, we observed in some instances that both the transcription-dependent (i.e., nuclear) and transcription-independent (i.e., cytoplasmic) functions of p53 were needed for optimal execution of synergistic apoptosis with nutlin ( Supplementary Fig. 8g) . These results are consistent with reports that the cytoplasmic functions of p53 can alone execute intrinsic apoptosis 34, 35 , whereas, in other contexts, p53's nuclear functions may be required to facilitate cytoplasmic-p53-mediated cell killing 27 . Collectively, our results show that combined targeting of EGFR-driven glucose metabolism and p53 induces marked synthetic lethality in primary GBM, in a manner dependent on the cytoplasmic functions of p53.
Priming metabolic nonresponders for apoptosis Our data led us to propose a model wherein inhibition of EGFR-driven glucose metabolism primes the apoptotic machinery, thus resulting in synergy with proapoptotic stimuli such as p53 activation. A logical prediction of this model is that direct targeting of glucose metabolism should mimic the effects of EGFR inhibition. In agreement with this Comparisons were made with two-tailed unpaired Student's t tests. *P < 0.05; **P < 0.01; ***P < 0.001.
prediction, addition of the glucose-metabolism inhibitor 2-deoxyglucose (2DG) stimulated apoptotic priming, binding of p53 to Bcl-xL, and synthetic lethality with nutlin in HK301 metabolic-responder cells. (Supplementary Fig. 9a,b,d ). In contrast, inhibition of oxidative phosphorylation with oligomycin (complex V/ATP synthase) or rotenone (complex I) did not synergize with nutlin treatment in HK301 gliomaspheres (Supplementary Fig. 9c,d) . Thus, decreased glucose metabolic flux alone, but not oxidative metabolism, appears to be sufficient for synergistic sensitivity to p53 activation. This result prompted us to consider whether modulating glucose consumption in nonresponders might result in a similar p53-dependent vulnerability. To investigate this possibility, we tested whether direct inhibition of glucose uptake through 2DG treatment, or targeting the kinase PI3K, a well-characterized driver of glucose metabolism 36 , would elicit apoptotic priming in two erlotinib metabolic nonresponders. In contrast to erlotinib treatment, acute inhibition of PI3K with pictilisib abrogated PI3K-AKT-mTOR signaling (Supplementary Fig. 9e ) and significantly decreased [ 18 F]FDG uptake in HK393 and HK254 cells (Fig. 5a) . The decrease in glucose consumption with pictilisib was associated with significantly higher apoptotic priming (Fig. 5b) ; 2DG treatment induced similar effects (Fig. 5a,b) . Therefore, erlotinib metabolic nonresponders can be primed for apoptosis after inhibition of glucose uptake. Notably, CRISPR-Cas9 targeting of TP53 in HK393 cells significantly suppressed priming mediated by 2DG or pictilisib (Fig. 5c) . Moreover, p53-dependent priming was associated with heightened Bcl-xL and p53 binding indicative of sequestration of p53 by Bcl-xL and blocking of apoptosis ( Fig. 5d and Supplementary Fig. 9f ). In agreement with this interpretation, combining 2DG or pictilisib with nutlin treatment caused significant p53-dependent synthetic lethality in erlotinib nonresponder cells (Fig. 5e,f) . Together, these data demonstrate that acute inhibition of glucose metabolism, either directly or with targeted therapy, promotes p53-dependent apoptotic priming in GBM, thereby creating a targetable vulnerability.
A noninvasive biomarker for combination treatment in vivo
Our results in cell culture show that combined targeting of oncogene-driven glucose metabolism and p53 has synergistic activity in primary GBM. This result led us to investigate whether this approach might be effective in orthotopic GBM xenograft models. For these studies, we used the MDM2 inhibitor idasanutlin, which is currently in clinical trials for many malignancies 37 . Given the uncertainty of penetration of idasanutlin into the central nervous system, we first demonstrated that idasanutlin accumulated in the brains of mice with a completely intact blood-brain barrier (~35% relative to plasma levels) and stabilized p53 in orthotopic-tumor-bearing mice (Supplementary Fig. 10a,b) .
Next, because perturbations in glucose metabolism with oncogene inhibition are required for synergistic sensitivity to p53 activation, we hypothesized that rapid attenuation of glucose uptake in vivo after erlotinib administration, as measured by [ 18 F]FDG positron emission tomography (PET), might serve as a noninvasive predictive biomarker for the therapeutic efficacy of combined erlotinib and idasanutlin treatment (Fig. 6a) . We observed, in orthotopic xenografts of a metabolic-responder gliomasphere (GBM39), that acute erlotinib treatment (75 mg/kg) rapidly decreased [ 18 F]FDG uptake (15 h after erlotinib administration; Online Methods) ( Fig. 6b and Supplementary Fig. 10c) . In separate groups of mice, we tested the individual drugs and the combination of daily erlotinib (75 mg/kg) and idasanutlin (50 mg/kg) treatment for up to 25 d. Comparisons for c and e used data sets from the last measurements and were made with two-tailed unpaired t tests. Kaplan-Meier survival analysis (log-rank) was used for f-i. **P < 0.01; ***P < 0.001.
The drug combination was tolerable over the treatment period; we observed a ~10% decrease in body weight, which was comparable to that after erlotinib treatment alone (Supplementary Fig. 10d ).
Relative to single-agent controls, combined treatment with erlotinib and idasanutlin demonstrated synergistic growth inhibition-as determined by secreted Gaussia luciferase 38 -in GBM39 intracranial-tumor-bearing mice (Fig. 6c) . In contrast, orthotopic xenografts of a nonmetabolic responder (HK393) showed neither changes in [ 18 F]FDG uptake with acute erlotinib (Fig. 6d and Supplementary  Fig. 10c ) nor synergistic activity with erlotinib and idasanutlin combination treatment (Fig. 6e) . Thus, noninvasive [ 18 F]FDG PET, used to measure rapid changes in glucose uptake with EGFR inhibition, was effective in predicting subsequent synergistic sensitivity to combined erlotinib and idasanutlin treatment. Finally, we evaluated the effects of the drug combination on overall survival in orthotopic xenografts of either two erlotinib metabolic responders (GBM39 and HK336) or two nonresponders (HK393 and GS025). All tumors were wild-type p53 (Supplementary Fig. 3a) . On the basis of evidence of tumor growth (as determined by Gaussia luciferase), mice were treated with vehicle, erlotinib, idasanutlin, or both for up to 25 d, and then treatment was halted, owing to limited availability of idasanutlin for these studies. Although all tumors had genetic alterations in EGFR (for example, mutation and/or amplification, or polysomy), the drug combination led to a pronounced increase in survival only in animals bearing erlotinib metabolic-responder GBM tumors (Fig. 6f-i) . Together, these data show that combined targeting of EGFR and p53 synergistically inhibits growth and prolongs survival in a subset of wild-type p53 GBM orthotopic xenografts, and that [ 18 F]FDG PET is a noninvasive predictive biomarker of sensitivity to this therapeutic strategy.
DISCUSSION
Here we found that acute EGFR inhibition rapidly decreases glucose utilization in a subset of patient-derived GBMs. As a consequence of this altered metabolic state, cells unexpectedly become primed for apoptosis via the cytoplasmic functions of p53. Accordingly, pharmacological p53 stabilization with a novel brain-penetrant small molecule was synthetically lethal with inhibition of EGFR-driven glucose uptake in primary orthotopic GBM models. Although these preclinical systems do not fully recapitulate the features of human GBM-consisting of an active immune system, pseudopalisading necrosis, and microvasculature proliferation-our results provide a proof of concept that deployment of targeted agents to perturb and exploit altered tumor metabolism may be an effective therapeutic strategy in GBM.
Most previous studies have suggested that the apoptotic functions of p53 are primarily exerted through its transcriptional activity. However, recent work supports the suggestion that the nontranscriptional functions of p53 have a critical role in triggering intrinsic apoptosis 26 . Our results demonstrate that cytoplasmic p53 couples oncogenic signaling to intrinsic apoptosis, which in this case is dependent on alterations in glucose utilization. However, the metabolic pathways downstream of glucose uptake that are responsible for this effect remain unknown. The observation that direct inhibition of oxidative phosphorylation does not synergize with p53 activation suggests that oxidation of glucose or other metabolites (for example, glutamine) is not required. Glucose can feed into many metabolic pathways including those for anabolic processes (for example, lipids, nucleotides, and amino acids), energetics, and enzyme function (for example, glycosylation and acetylation). Thus, attenuated glucose consumption may affect multiple pathways and induce metabolic stress 39 and/or decrease donor metabolic substrates 40, 41 to levels sufficient to stimulate the cytoplasmic functions of p53. Future studies are required to specifically define these metabolic nodes that render GBM cells exquisitely susceptible to cytoplasmic-p53-mediated apoptosis. The results may reveal analogous therapeutic vulnerabilities to exploit GBM tumors for p53-dependent cell death.
More work is also needed to understand precisely how cytoplasmic p53 triggers intrinsic apoptosis in GBM cells. Considerable evidence indicates that cytoplasmic p53 possesses similar functionality to that of proapoptotic BH3 proteins; for example, it can activate the proapoptotic effectors BAK 22, 42 or BAX both directly 21 and indirectly via neutralizing antiapoptotic Bcl2 proteins 22 . Our results support this role for cytoplasmic p53, whereby, after glucose metabolism is attenuated, p53 engages the intrinsic apoptotic machinery via binding to the antiapoptotic protein Bcl-xL. Despite minimal cell death, the increased occupancy of Bcl-xL with p53 lowers the apoptotic threshold and creates a dependency on Bcl-xL to block p53-mediated cell death. Targeting this interaction (for example, BCL-xL inhibition or MDM2 antagonism) liberated p53 from Bcl-xL, a result that coincided with BAX activation and cytoplasmic-p53-dependent intrinsic apoptosis. Thus, 'free' cytoplasmic p53 may directly activate BAX and promote apoptosis in response to this therapeutic combination. Finally, it is important to note that although cytoplasmic p53 was necessary for the execution of synergistic apoptosis with either Bcl-xL or MDM2 inhibition, it was universally sufficient only in the context of BclxL inhibition. This apparent discrepancy may be explained through observations that, in some instances, the displacement of cytoplasmic p53 from Bcl-xL requires the binding of the p53-transcriptional-target gene PUMA (official symbol BBC3) 27, 43 . Because MDM2 antagonists stimulate nuclear p53 transcriptional activity, including expression of PUMA, it possible that in some contexts the transcription-dependent functions of p53 are required to facilitate cytoplasmic-p53-mediated apoptosis in GBM.
Notably, neither genetic alterations in EGFR nor the degree of EGFR-activity inhibition was sufficient to predict a metabolic response to EGFR tyrosine kinase inhibition in our GBM samples. Several molecular mechanisms have been described that enable dynamic compensatory responses to EGFR-directed therapy in GBM 44 . Thus, it is likely that, despite robust inhibition of EGFR, some tumors quickly reconfigure their molecular circuitry to preserve downstream signaling flux and drive glucose consumption 45 . Given the breadth of potential adaptive mechanisms, coupled with the molecular heterogeneity of GBM, genetic biomarkers alone may be insufficient to predict responses to this approach. Our results emphasize the value of a functional biomarker, in this case changes in glucose uptake 46 , as a means to rapidly stratify metabolic responders and nonresponders.
Together, our findings provide a rationale for the clinical evaluation of combined targeting of oncogene-driven glucose metabolism (for example, inhibition of EGFR or PI3K) and p53 in patients with GBM. Furthermore, we propose a new clinical application of [ 18 F]FDG PET to assess whether targeted drugs induce a metabolic vulnerability that can be exploited. On the basis of our data showing that changes in [ 18 F]FDG accumulation can be observed within hours after EGFR-inhibitor treatment, [ 18 F]FDG PET may serve as a rapid, noninvasive functional biomarker to predict synergistic sensitivity to p53 activation. This noninvasive analysis may be particularly valuable for malignant brain tumors, in which pharmacokinetic and pharmacodynamic assessment is extremely difficult and impractical. Although there are concerns that [ 18 F]FDG PET cannot properly delineate glucose uptake in tumor tissue versus healthy brain tissue, delayed imaging protocols 47 (used here for the mouse studies) and parametric-response maps with magnetic resonance imaging fusion can be useful for quantifying the changes in tumor [ 18 F]FDG consumption. Finally, targeting oncogenes that drive glucose uptake in other cancers may evoke similar p53-dependent vulnerabilities. Future work is required to assess the applicability of this concept to other oncogenic drivers and cancers.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Mice. Female NOD scid gamma (NSG) mice, 6-8 weeks of age, were purchased from the University of California Los Angeles (UCLA) Medical Center animalbreeding facility. Male CD-1 mice, 6-8 weeks of age, were purchased from Charles River. All mice were kept under defined pathogen-free conditions at the AAALAC-approved animal facility of the Division of Laboratory Animals (DLAM) at UCLA. All animal experiments were performed with the approval of the UCLA Office of Animal Resource Oversight (OARO).
Patient-derived GBM cells. After explicit informed consent was obtained from patients, all patient tissue used to derive GBM cell cultures was obtained through the UCLA Institutional Review Board (IRB) protocol 10-000655. As previously described 12 , primary GBM cells were established and maintained in gliomasphere conditions consisting of DMEM/F12 (Gibco), B27 (Invitrogen), penicillin-streptomycin (Invitrogen), and GlutaMAX (Invitrogen) supplemented with heparin (5 µg/mL, Sigma), EGF (50 ng/mL, Sigma), and FGF (20 ng/mL, Sigma). All cells were grown under 37 °C, 20% O 2 , and 5% CO 2 and were routinely monitored and tested negative for the presence of mycoplasma with a commercially available kit (MycoAlert, Lonza). At the time of experiments, most HK lines used were between 20 and 30 passages (exceptions HK385 p8 and HK336 p15), whereas GS and GBM39 lines were used at fewer than ten passages. All cells were authenticated by short tandem repeat (STR) analysis. Glucose, glutamine, and lactate measurements. Cellular glucose consumption and lactate production were measured with a Nova Biomedical BioProfile Basic Analyzer. Briefly, cells were plated in 1 × 10 5 cells/mL in 2 mL of gliomasphere conditions, under the appropriate drug treatments. 12 h after drug treatment, 1 mL of medium was removed from each sample and analyzed in the Nova BioProfile analyzer. Measurements were normalized to cell number.
Reagents and antibodies.
Annexin V apoptosis assay. Cells were collected and analyzed for annexin V and PI staining according to the manufacturer's protocol (BD Biosciences). Briefly, cells were plated at 5 × 10 4 cells/mL and treated with the appropriate drugs. At the indicated time points, cells were collected, trypsinized, washed with PBS, and stained with annexin V and PI for 15 min. Samples were then analyzed with a BD LSRII flow cytometer.
Immunoblotting. Cells were collected and lysed in RIPA buffer (Boston BioProducts) containing Halt Protease and Phosphatase Inhibitor (Thermo Fisher Scientific). Lysates were centrifuged at 14,000g for 15 min at 4 °C. Protein samples were then boiled in NuPAGE LDS Sample Buffer (Invitrogen) and NuPAGE Sample Reducing Agent (Invitrogen), separated with SDS-PAGE on 12% Bis-Tris gels (Invitrogen) and transferred to nitrocellulose membranes (GE Healthcare). Immunoblotting was performed per the antibody manufacturers' specifications, as mentioned previously. Membranes were developed with the SuperSignal system (Thermo Fisher Scientific).
Immunoprecipitation. Cells were collected, washed once with PBS, and incubated in IP lysis buffer (25 mM Tris-HCL, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, and 5% glycerol) at 4 °C for 15 min. 300-500 µg of each sample was then precleared in Protein A/G Plus Agarose Beads (Thermo Fisher Scientific) for 1 h. After preclearing, samples were then incubated with antibody-bead conjugates overnight according to the manufacturer's specifications and as mentioned previously. The samples were then centrifuged at 1,000g for 1 min, and the beads were washed with 500 µL of IP lysis buffer five times. Proteins were eluted from the beads by boiling in 2× LDS Sample Buffer (Invitrogen) at 95 °C for 5 min. Samples were analyzed by immunoblotting as previously described. Immunoprecipitation antibodies were diluted according to the manufacturer's instructions (1:200 for p53).
Dynamic BH3 profiling. GBM gliomaspheres were first disassociated into single-cell suspensions with TrypLE (Gibco) and resuspended in MEB buffer (150 mM mannitol, 10 mM HEPES-KOH, 50 mM KCl, 0.02 mM EGTA, 0.02 mM EDTA, 0.1% BSA, and 5 mM succinate). 50 µL of cell suspension (3 × 10 4 cells/well) was plated in wells holding 50 µL MEB buffer containing 0.002% digitonin and the indicated peptides in 96-well plates. Plates were then incubated at 25 °C for 50 min. Cells were then fixed with 4% paraformaldehyde for 10 min and neutralized with N2 buffer (1.7 M Tris and 1.25 M glycine, pH 9.1) for 5 min. Samples were stained overnight with 20 µL of staining solution (10% BSA and 2% Tween 20 in PBS) containing DAPI and anti-cytochrome c (BioLegend clone 6H2.B4, cat. no. 612310). The following day, cytochrome c release was quantified with a BD LSRII flow cytometer. Measurements were normalized to appropriate controls that do not promote cytochrome c release (DMSO and inactive PUMA2A peptide). Change in priming refers to the difference in the amount of cytochrome c release between vehicle-treated cells and drug-treated cells.
Plasma-membrane protein extraction. 1 × 10 7 cells were treated with the indicated drugs. After 4 h of treatment, cells were collected, washed once with ice-cold PBS, and lysed with a Dounce homogenizer. Plasma-membrane protein extraction was performed according to the manufacturer's protocol (BioVision), and isolated proteins were then subjected to immunoblotting. BAX oligomerization. 7.5 × 10 5 cells were treated with the indicated drugs. After 24 h of treatment, cells were collected, washed once with ice-cold PBS, and resuspended in 1 mM bismaleimidohexane (BMH) in PBS for 30 min. Cells were then pelleted and lysed for immunoblotting, as described above.
Cytochrome c detection. 5 million cells were plated at a concentration of 1 × 10 5 cells/mL and treated with the indicated drugs. After 24 h of treatment, cells were collected and washed once with ice-cold PBS. Subcellular fractionation was then performed with a mitochondrial isolation kit (Thermo Fisher Scientific, 89874). Both cytoplasmic and mitochondrial fractions were subjected with a 1290 Infinity LC system (Agilent). The mobile phase was composed of solvent A consisting of 0.1% formic acid in Milli-Q water and solvent B consisting of 0.1% formic acid in acetonitrile. Analytes were eluted with a gradient of 5% B (0-4 min), 5-99% B (4-32 min), and 99% B (32-36 min), and then returned to 5% B for 12 min to reequilibrate between injections. Injections of 20 µL into the chromatographic system were used with a solvent flow rate of 0.10 mL/min. Mass spectrometry was performed on a 6460 triple-quadrupole LC/MS system (Agilent). Ionization was achieved by using electrospray in the positive mode, and data acquisition was performed in multiple reaction monitoring (MRM) mode. The MRM transition used for idasanutlin detection was m/z 616.2 → 421.2 with a fragmentor voltage of 114 V and a collision energy of 20 eV. The analyte signal was normalized to the internal standard, and concentrations were determined by comparison to the calibration curve (0.5, 5, 50, 250, 500, and 2,000 nM). Idasanutlin brain concentrations were adjusted by 1.4% of the mouse brain weight for the residual blood in the brain vasculature, as described by Dai et al. 51 .
Secreted Gaussia luciferase measurements. Cells were infected with a lentiviral vector containing a secreted Gaussia luciferase (sGluc)-encoding reporter gene (Targeting Systems no. GL-GFP) and intracranially implanted into the right striatum in mice (4 × 10 5 cells/mouse). To measure the levels of secreted Gaussia luciferase (sGluc), 6 µL of blood was collected from the tail vein and immediately mixed with 50 mM EDTA to prevent coagulation. Gluc activity was obtained by measuring chemiluminescence after injection of 100 µL of 100 µM coelentarazine (Nanolight) in a 96-well plate, as described before 38 .
Synergy-score calculations. 1.0 × 10 5 GBM cells were plated in triplicate and treated with erlotinib, nutlin, or both at multiple concentrations by using a matrix in which each drug was added to the cells at six concentrations (0-10 µM). Annexin V staining was measured after 72 h of treatment. Using Chalice software, as described in Lehár et al., the response to the combination treatment was compared with the responses to single-agent treatments, and the combinatorial effects were calculated by using the synergy score 33 .
DNA sequencing. Targeted sequencing was performed for samples HK206, HK217, HK250, and HK296 for the following genes BCL11A, BCL11B, BRAF, CDKN2A, CHEK2, EGFR, ERBB2, IDH1, IDH2, MSH6, NF1, PIK3CA, PIK3R1, PTEN, RB1, and TP53 with an Illumina MiSeq platform. There were 1 to 2 million reads per sample, with an average coverage of 230 per gene. Copy-number variants were determined for these samples with a whole-genome SNP array. The genetic profile of GBM39 has previously been reported 45 .
Whole-exome sequencing was performed for samples HK157, HK229, HK248, HK250, HK254, HK296, HK301, HK336, HK350, HK390, and HK393, and was carried out at SeqWright. Samples were grouped into two pools with separate capture reactions. Nextera Rapid capture and library preparation were used, and sequencing was performed on the HiSeq 2500 platform with 2 × 100 bp and 100× on-target coverage in two full rapid runs, each with one normal diploid control. Copy-number analysis for these samples was carried out with EXCAVATOR software 52 .
For DNA sequencing of gliomasphere samples GS024, GS017, and GS025, the library construction was performed with the SeqCap EZ System from NimbleGen according to the manufacturer's instructions. Briefly, genomic DNA was sheared and size-selected to approximately 300 bp, and the ends were repaired and ligated to specific adapters and multiplexing indexes. Fragments were then incubated with SeqCap biotinylated DNA baits after LM-PCR, and the hybrids were purified with streptavidin-coated magnetic beads. After amplification of 18 or fewer PCR cycles, the libraries were then sequenced on the HiSeq 3000 platform from Illumina, using 150-bp paired-end reads.
The sequence data were aligned to the GRCh37 human reference genome with BWA v0.7.7-r411. PCR duplicates were marked with the MarkDuplicates program in the Picard-tools-1.115 tool set. GATK v3.2-2 was used for insertions and deletions (INDEL) realignment and base quality recalibration. Exome coverage was calculated with bedtools. Samtools was used to call the single-nucleotide variants (SNVs) and small INDELs. Varscan2 was used to call the somatic SNVs. All variants were annotated with the Annovar program.
Annotation of TCGA samples. 273 GBM samples from TCGA were analyzed for genetic alterations in EGFR, p53, and p53-regulated pathways. Cooccurrences of mutations were examined, and only significant interactions are displayed. Data were analyzed with cBioPortal as previously described 53, 54 .
Fluorescence in situ hybridization (FISH). Fluorescence in situ hybridization (FISH) was performed with a commercially available fluorescently labeled dualcolor EGFR (red)/CEP 7(green) probe (Abbott-Molecular). FISH hybridization and analyses were performed on cell lines, by following the manufacturer's suggested protocols. The cells were counterstained with DAPI, and the fluorescentprobe signals were imaged under a Zeiss (Axiophot) Fluorescence Microscope equipped with dual-and triple-color filters.
Statistical analysis.
Comparisons were made with two-tailed unpaired Student's t tests, and P values <0.05 were considered statistically significant. All data from multiple independent experiments were assumed to be of normal variance. For each experiment, replicates are as noted in the figure legends. Data represent mean ± s.d. values unless otherwise indicated. All statistical analyses were calculated in Prism 7.0 (GraphPad). For all in vitro and in vivo experiments, no statistical method was used to predetermine sample size, and no samples were excluded. For in vivo tumor measurements, the last data sets were used for comparisons between groups. As described above, all mice were randomized before studies. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined.
No formal statistical method was used to pre-determine sample size. Sample sizes were estimated based off pilot experiments and from previous literature.
Data exclusions
Describe any data exclusions. No data were excluded from these studies.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful for all experiments.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For mouse xenograft studies, mice were allocated into the various treatment groups so that each treatment arm had no statistically significant difference in mean tumor burden, as assessed by gaussia luciferase, measured immediately preceding group allocations.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Investigators were not blinded to group allocation Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
